European Experts Recommended Against Approving Novartis AG's Antifungal Drug Mycograb
LONDON, Nov 17 (Reuters) - A panel of European experts has recommended against approving Novartis AG's (NOVN.VX: Quote, Profile, Research) antifungal drug Mycograb, which the Swiss group acquired with the purchase of British biotech firm NeuTec Pharma in June.